CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
Multi-center, open-label, non-comparative safety and efficacy study with 52 Weeks of
 treatment on the face and trunk for acne vulgaris.
To determine the safety and efficacy of CD5789 (trifarotene) 50 µg/g cream in the long-term
 treatment (up to 52 Weeks) of subjects with acne vulgaris. Efficacy will be evaluated as a
 secondary objective.
Inclusion Criteria:

 -  The Subject has a facial acne severity grade of IGA grade 3 (moderate) at Screening
 and Baseline visits.

 -  The Subject has a minimum of 20 inflammatory lesions and 25 non-inflammatory lesions
 at Screening and Baseline visits on the face.

 -  Exclusion Criteria:

 -  The subject has severe forms of acne (acne conglobata, acne fulminans) or secondary
 acne form (chloracne, drug-induced acne, etc.).

 -  The Subject has more than 1 nodule on the face at Screening and at Baseline visits.

 -  The Subject has any acne cyst on the face at Screening and at Baseline visits.